Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P49675: Variant p.Glu169Gly

Steroidogenic acute regulatory protein, mitochondrial
Gene: STAR
Feedback?
Variant information Variant position: help 169 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamate (E) to Glycine (G) at position 169 (E169G, p.Glu169Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AH1; partial loss of activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 169 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 285 The length of the canonical sequence.
Location on the sequence: help PNVKEIKVLQKIGKDTFITH E LAAEAAGNLVGPRDFVSVRC The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         PNVKEIKVL-----------------------QKIGKDTFITHELAAEAAGNLVG---------------------------------PRDFVSVRC

Mouse                         PNVKEIKVL-----------------------QRIGKDTVI

Rat                           PNVKEIKVL-----------------------KKIGKDTVI

Pig                           PSVKKIKIL-----------------------QKIGKDTVI

Bovine                        PNVKEIKVL-----------------------QKIGKDTVI

Sheep                         PSVKEIKVL-----------------------QKIGKDTII

Horse                         PNVKEIKVL-----------------------QKIGKDTVI

Chicken                       PSVKEVKIL-----------------------QRVGKDTLI

Xenopus laevis                PNVKEVKIL-----------------------QKIGKDTVI

Zebrafish                     PNVKQVKIL-----------------------QKIGQETMI

Drosophila                    PKVAAAASVGVGPPPNSPRLAAAGSTFGSGNSSGSGADQLA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 64 – 285 Steroidogenic acute regulatory protein, mitochondrial
Domain 67 – 280 START
Beta strand 161 – 171



Literature citations
The pathophysiology and genetics of congenital lipoid adrenal hyperplasia.
Bose H.S.; Sugawara T.; Strauss J.F. III; Miller W.L.;
N. Engl. J. Med. 335:1870-1878(1996)
Cited for: VARIANTS AH1 GLY-169; LYS-169; LEU-182; VAL-218; ARG-272 DEL AND PRO-275; CHARACTERIZATION OF VARIANTS AH1 GLY-169; LYS-169; LEU-182; VAL-218; ARG-272 DEL AND PRO-275; CATALYTIC ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.